BACKGROUND Natalizumab is a new therapeutic option for relapsing-remitting multiple sclerosis. As with other antibody therapies, hypersensitivity reactions have been observed. In the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) trial, infusion-related hypersensitivity reactions developed in 4% of patients, usually within 2 hours after starting the infusion....

Subtyping relapsing–remitting multiple sclerosis (RRMS) patients may help predict disease progression and triage for treatment. We aimed to subtype RRMS by structural MRI investigate their clinical significances. 155 relapse-remitting MS 210 healthy controls (HC) were retrospectively enrolled with 3DT1, diffusion tensor imaging (DTI) resting-state functional MRI. Z scores of cortical deep gray ...

OBJECTIVE To study the relation between self reported stressful life events not related to multiple sclerosis and the occurrence of exacerbations in relapsing-remitting multiple sclerosis. DESIGN Longitudinal, prospective cohort study. SETTING Outpatient clinic of department of neurology in the Netherlands. PARTICIPANTS Patients aged 18-55 with relapsing-remitting multiple sclerosis, who ...

BACKGROUND AND PURPOSE Vitamin D deficiency is a recognized risk factor for multiple sclerosis (MS) and is associated with increased disease activity. It has also been proposed that the lower the vitamin D levels are, the higher is the handicap. METHODS To refine the links between vitamin D insufficiency and disability in MS patients, a retrospective cohort analysis was performed including 18...

INTRODUCTION Progressive hemifacial atrophy (PHA) is a rare disorder characterized by unilateral facial atrophy affecting the skin, subcutaneous tissue, and fat, muscle, and osteocartilagenous structures creating a sunken hemiface appearance.Etiopathogenesis of PHA is poorly understood; no definitive treatment is currently available. CLINICAL FINDINGS We report a 41-year-old woman with PHA wh...

OBJECTIVE To investigate the potential role of prokineticin 2 (PK2), a bioactive peptide involved in multiple biological functions including immune modulation, in CNS autoimmune demyelinating disease. METHODS We investigated the expression of PK2 in mice with experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), and in patients with relapsing-remitting ...

BACKGROUND Statins have anti-inflammatory and immunomodulatory properties in addition to their lipid-lowering effects. Currently, the effects of statins on multiple sclerosis are still controversial. Therefore, randomized clinical trials are needed to provide better evidence on the therapeutic potential of statins in multiple sclerosis. The SWiss Atorvastatin and Interferon Beta-1b trial in Mul...